NCT07219485View on ClinicalTrials.gov

A Study of Pitolisant in Participants With Prader-Willi Syndrome

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2030

Conditions
Prader-Willi Syndrome
Interventions
DRUG

Pitolisant

"* Pitolisant 4.45 mg tablets~* Pitolisant 17.8 mg tablets"

Trial Locations (1)

27560

Science 37, Morrisville

All Listed Sponsors
lead

Harmony Biosciences Management, Inc.

INDUSTRY